On Tuesday, UroGen Pharma Ltd (NASDAQ: URGN) opened lower -3.89% from the last session, before settling in for the closing price of $11.06. Price fluctuations for URGN have ranged from $9.03 to $20.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 13165.79%. Company’s average yearly earnings per share was noted 2.84% at the time writing. With a float of $38.22 million, this company’s outstanding shares have now reached $42.23 million.
Let’s determine the extent of company efficiency that accounts for 235 employees. In terms of profitability, gross margin is 90.18%, operating margin of -107.06%, and the pretax margin is -137.22%.
UroGen Pharma Ltd (URGN) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of UroGen Pharma Ltd is 17.09%, while institutional ownership is 80.31%. The most recent insider transaction that took place on Jan 31 ’25, was worth 50,698. In this transaction Chief Medical Officer of this company sold 4,551 shares at a rate of $11.14, taking the stock ownership to the 145,666 shares. Before that another transaction happened on Jan 31 ’25, when Company’s General Counsel sold 7,379 for $11.14, making the entire transaction worth $82,202. This insider now owns 26,468 shares in total.
UroGen Pharma Ltd (URGN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 2.84% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Check out the current performance indicators for UroGen Pharma Ltd (URGN). In the past quarter, the stock posted a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.22, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Looking closely at UroGen Pharma Ltd (NASDAQ: URGN), its last 5-days average volume was 0.5 million, which is a jump from its year-to-date volume of 0.39 million. As of the previous 9 days, the stock’s Stochastic %D was 13.88%. Additionally, its Average True Range was 0.61.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 36.87%, which indicates a significant increase from 3.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.91% in the past 14 days, which was lower than the 43.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.68, while its 200-day Moving Average is $12.78. However, in the short run, UroGen Pharma Ltd’s stock first resistance to watch stands at $11.11. Second resistance stands at $11.60. The third major resistance level sits at $11.87. If the price goes on to break the first support level at $10.35, it is likely to go to the next support level at $10.08. Now, if the price goes above the second support level, the third support stands at $9.59.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
There are currently 46,094K shares outstanding in the company with a market cap of 489.98 million. Presently, the company’s annual sales total 90,400 K according to its annual income of -126,870 K. Last quarter, the company’s sales amounted to 24,570 K and its income totaled -37,510 K.
